| Entries |
| Document | Title | Date |
|---|
| 20130102533 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 04-25-2013 |
| 20130196914 | Methods for Chronic Pain Management and Treatment using HCG - A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug. | 08-01-2013 |
| 20140249082 | Pharmaceutical Preparation Comprising Recombinant HcG - The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include α2,3, α2,6, and, optionally, α2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line. | 09-04-2014 |
| 20150057224 | METHODS FOR CHRONIC PAIN MANAGEMENT AND TREATMENT USING HCG - A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonodotropin (uHCG and/or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide, or be equivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A kit is also described, which includes a supply of the HCG-related drug, a delivery device, and a label that identifies chronic pain or central sensitization as an indication of the drug. | 02-26-2015 |
| 20150072933 | NOVEL SEQUENCES FOR THE CONTROL OF REPRODUCTION IN FISH - The present invention relates to novel peptide sequences, compositions and methods for controlling fish reproduction. More particularly, the invention provides novel Neurokinin B peptides NKF and NKB and analogues thereof that regulate reproduction in fish. The invention further provides preprohormone thereof comprising at least one of a first peptide fragment of the amino acid sequence X | 03-12-2015 |
| 20150293129 | DETECTION AND TREATMENT OF PREGNANCY COMPLICATIONS - Disclosed herein is a method of of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient- subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b). | 10-15-2015 |
